Active surveillance: towards a new paradigm in the management of early prostate cancer (Q35648389)

9 August 2017

1 reference

title

Active surveillance: towards a new paradigm in the management of early prostate cancer (English)

1 reference

9 August 2017

1 reference

Chris Parker

1

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Lancet Oncology Commission

9 August 2017

published in

1 reference

9 August 2017

volume

5

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

101-106

1 reference

Understanding and appreciating overdiagnosis in the PSA era

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Survival prospects after screen-detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Clinical observations on the doubling time of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

The management of PSA failure after radical radiotherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

PSA doubling time of prostate carcinoma managed with watchful observation alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901384-1

7 January 2021

10.1016/S1470-2045(04)01384-1

Identifiers

DOI

1 reference

9 August 2017

1 reference